Morepen Laboratories Limited has informed the Exchange about Bagging/Receiving of orders/contracts
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 3.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Morepen Laboratories has won a ₹825 crore (USD 91 million) international order from a leading global pharma major. The contract is for CDMO (Contract Development and Manufacturing Organization) services, marking Morepen's entry into the high-growth CDMO segment. Supplies are expected to commence within 4-5 months, with full execution scheduled over 12-15 months from the date of award, subject to standard regulatory and operational approvals. The company has confirmed no promoter group interest in the awarding entity and that this is not a related party transaction. The order represents a significant revenue opportunity and a strategic diversification beyond Morepen's traditional API business.
This is a sizeable export order in hard currency that strengthens the revenue pipeline and marks a strategic move into the CDMO segment, which typically carries higher margins. Positive for the stock in the near term as it validates Morepen's global capabilities and could drive re-rating.